👨⚕️ The collaboration between TECNIC Bioprocess Solutions and BYOTIC aims to advance personalized medicine and innovative therapies.
🔬 The project focuses on the development of single-use bioreactors for autologous cell therapy, reducing the need for repeated sterilization and contamination risks.
💡 TECNIC’s innovative design incorporates advanced perfusion technology and control software for optimal production of cell-based biopharmaceuticals.
♻️ The modular and flexible design of the bioreactors enhances sustainability and adaptability, reducing costs and improving production efficiency.
🤝 Strategic collaborations with leading institutions such as Universitat Autònoma de Barcelona and Banc de Sang i Teixits de Catalunya strengthen research and development capabilities.
💪 This project not only improves personalized treatments but also sets new standards for efficient and safe production of biopharmaceuticals.
🌍 TECNIC’s advancements in bioprocessing technology contribute to a future where personalized medicine is accessible to all, transforming healthcare.
💼 TECNIC Bioprocess Solutions’ contribution to knowledge creation and technology transfer fosters economic and technological development.
Introduction:
TECNIC Bioprocess Solutions, in collaboration with BYOTIC, has been selected for the phase 1 of a pre-commercial public procurement process to develop an intelligent platform for parallel single-use bioreactors. This platform aims to be used in autologous cell therapy, representing a significant step towards advancing cutting-edge cellular therapies.
- TECNIC Bioprocess Solutions and BYOTIC have formed a strategic partnership to develop single-use bioreactors for personalized medicine.
- The development includes advanced perfusion technologies and sophisticated control systems to optimize the production of cell-based biopharmaceuticals.
- Single-use bioreactors eliminate the need for repeated cleaning and sterilization, reducing the risk of contamination and increasing production efficiency.
- The integration of perfusion technology in the bioreactors allows for efficient feeding and waste removal, maintaining cell viability during prolonged periods of cultivation.
- The advanced control and monitoring software ensures real-time supervision of critical parameters, optimizing the production process and reducing the risk of errors.
Conclusion:
TECNIC Bioprocess Solutions, in collaboration with BYOTIC, has been selected for the development of an intelligent platform for single-use bioreactors in autologous cell therapy. This project represents a significant advancement in personalized medicine, as it combines innovative technologies and principles of sustainability to enhance the production of cell-based biopharmaceuticals. The use of single-use bioreactors reduces costs, improves production efficiency, and ensures the quality and safety of personalized treatments. The collaboration with leading institutions in the field and the emphasis on continuous improvement and responsible innovation position TECNIC as a leader in the global market of biopharmaceuticals, driving the accessibility and effectiveness of personalized therapies.
